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1.1 Introduction 
L-glutamate is the major excitatory neurotransmitter in the mammalian central nervous system (CNS) 
and plays a fundamental role in the control of motor function, cognition and mood. The physiological 
effects of glutamate are mediated through two functionally distinct receptor families. While activation 
of metabotropic (G-protein coupled) glutamate receptors results in modulation of neuronal excitability 
and transmission, the ionotropic glutamate receptors (ligand-gated ion channels) are responsible for 
mediating the fast synaptic response to extracellular glutamate. The ionotropic glutamate receptors are 
divided up into three subclasses on the basis of molecular and pharmacological differences and are 
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⎮ Non Standard Abbreviations: α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA); 
Attention Deficit Hyperactivity Disorder (ADHD); Central Nervous System (CNS); Cyclothiazide 
(CTZ); Fluorowillardine (FW); Glutamate Receptor (GluR); Ligand Binding Domain (LBD); Human 
Embryonic Kidney (HEK); K+ channel from Streptomyces lividans (KcsA); Leucine Isoleucine Valine 
binding protein (LIVbp); Long Term Potentiation (LTP); N-Methyl-D-Aspartate (NMDA); 
Transmembrane (TM). 
 
named after the agonists that were originally identified to selectively activate them: AMPA (α-amino-3-
hydroxy-5-methyl-4-isoxazole-propionic acid), NMDA (N-methyl-D-aspartate) and kainate (2-carboxy-
3-carboxymethyl-4-isopropenylpyrrolidine)1,2. AMPA receptors are ubiquitous in the CNS and mediate 
the majority of fast amino acid neurotransmission. They are also critical to synaptic plasticity and the 
induction of long-term potentiation (LTP), the use-dependent increase in synaptic efficacy widely 
considered a substrate for learning and memory. Given the key role of AMPA receptors in brain 
physiology, a lot of early effort in terms of pharmaceutical drug development focused on the 
identification of AMPA receptor antagonists as a means of ameliorating the excitotoxic effects of 
excessive glutamate such as occurs during brain injury or ischemia. However, these compounds have 
failed to progress due to a variety of side effects including psychotomimetic-like effects and memory 
impairment.  More recently, there has been a growing appreciation of the therapeutic potential of 
positive allosteric modulators of the AMPA receptor as a means of potentiating glutamatergic function 
while avoiding the attendant excitotoxic effects of direct agonists.  A number of distinct classes of 
AMPA receptor positive allosteric modulators have been described in recent years that have been 
demonstrated to modulate key functional properties of AMPA receptors such as desensitization (the 
process of ion channel closure with agonist remaining bound to the receptor) and deactivation (the 
process of channel inactivation following the dissociation of agonist) which in turn modulate the 
amplitude and duration of synaptic responses to glutamate.  These molecules have been shown to 
enhance synaptic transmission and LTP and increase the expression of neurotrophic factors. As such, 
the potential therapeutic utility of these molecules is being investigated for a variety of clinical 
indications such as schizophrenia, depression, Alzheimer’s disease, Parkinson’s disease, ADHD, and 
respiratory depression. Clinical data, however, is still quite limited with only 4 (CX516, Ampalex), 43 
(CX717, structure not disclosed), 9 (CX691/Org 24448, farampator) and 21 (LY451395), having 
progressed to phase II trials. Despite concerns over potential toxicity issues with these compounds, 
given the link with excitotoxicity that has been associated with excessive activation of ionotropic 
glutamate receptors, clinical studies carried out to date have demonstrated that they have are tolerated 
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than would expected. In fact, positive allosteric modulators of the AMPA receptor appear to have 
relatively few adverse effects at therapeutically relevant doses, and indeed, have been shown to protect 
neurons against neurotoxic insults.3 These seemingly paradoxical findings have been linked to the 
induction (by AMPA receptor positive modulators) of growth factors, such as BDNF which is known to 
possess neuroprotective properties. 4 
The basic pharmacology and clinical potential of positive allosteric modulators of the AMPA receptor 
have been the subject of a number of extensive reviews5,6,7,8,9,10 which provide a broad perspective on 
AMPA receptors, including the mechanisms of action of various classes of modulator, the clinical, and 
indeed, emerging clinical evidence supporting their use in the aforementioned indications.  In this 
article we will focus briefly on the recent developments in elucidating receptor structure and its relation 
to channel biophysics, followed by an overview of the various chemotypes known to modulate the 
channel. 
 
1.2 Receptor structure & function 
AMPA receptor subunits are encoded by four distinct genes labeled GluA1 to GluA4, which are 
known synonymously as GluR1 to GluR4.11 Each of the four subunits exists as two splice variants 
termed ‘flip’ (i) or ‘flop’ (o) which differ by less than 10 amino acids in their extracellular domain. In 
particular, the Asn residue at position 754 is mutated to Ser in the ‘flip’ isoform.  Additional complexity 
in the receptor stems from RNA editing, the most well characterized variant being a Gln/Arg site within 
the ion-channel pore of GluA2, resulting in reduced calcium permeability. An additional Arg/Gly 
editing site has been identified in the extracellular domains of GluA2-4.  
The AMPA receptor is tetrameric, each monomer having a modular structure (Figure 1) comprising 
two large extracellular domains; the N-terminal domain (NTD) and the ligand-binding domain (LBD), 
both of which show homology to LIVbp; a transmembrane (TM) domain showing homology to 
potassium channels such as KcsA and a C-terminal domain which varies greatly in size. The structure of 
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4s.14, 17,18, 19. 
the intact rat GluA2 receptor has recently been determined 12,13 and provides fascinating insights into 
the architecture and function of these receptors. Although the intact receptor is notionally a tetramer, 
this is usually comprised of heteromeric subunits from GluA1-4. The precise composition of the 
functional heterotetramer is variable, however, each generally contains at least one GluR2 subunit 
which is believed to be important in controlling Ca2+ permeability. The structure demonstrates a 
symmetry mismatch, with four fold symmetry in the transmembrane regions but a two fold, dimer-of-
dimer arrangement in the extracellular regions, which appears integral to the gating mechanism of all 
ionotropic glutamate receptors. Crystal structures of individual GluA2,A3,A4 receptor domains have 
also been determined14,15,16 and there have been extensive studies of the GluA2 LBD and its 
interactions with modulators of various pharmacologie
1.2.1 Allosteric binding site & functional relevance 
Crystal structures have shown that within a tetrameric AMPA receptor the LBD is a functional dimer, 
and have revealed multiple sites at which ligands can bind to influence function. The orthosteric 
glutamate-binding site is located within the clamshell structure of an individual LBD, and it is clear12, 20, 
21 that binding of ligands at this site induces conformational changes which are propagated to the 
transmembrane region to facilitate gating. Specifically, binding of an agonist induces closure of the 
clamshell and the force exerted by this domain movement is mechanically transmitted into opening of 
the pore. Receptor desensitization occurs when the interface between two closed, agonist-bound 
clamshells within a functional dimer becomes disrupted, removing the leverage required to force the 
channel open. Knowledge of the structural changes underlying receptor function has focused the design 
and development of allosteric AMPA modulators towards this interface, because compounds which bind 
to and stabilize it can reduce both desensitization and deactivation,17,19, 22 and thereby enhance AMPA 
currents. 
 
 
 Figure 1: (A) shows a schematic of the domain structure of an iGluR monomer, comprising the large 
N-terminal domain (yellow), the ligand-binding domain (red) which bears the agonist site, and the 
transmembrane region (blue). (B) shows a cartoon depiction of one monomer from the GluA2 crystal 
structure.12, 23  
 
 
Figure 2: Binding modes of diverse AMPA positive allosteric modulators. Each of these structures was 
determined using a variant of the GluA2 LBD. The view is down the twofold axis relating monomers 
within the LBD dimer. (a) Crystal structure of 2 (aniracetam) bound to the GluA2 flop LBD, showing 2 
spanning the central twofold axis. As a result there are two overlapping binding sites related by the 
twofold symmetry, though only one molecule is shown here for clarity. (b) Crystal structure of 13 
(cyclothiazide) bound to the GluA2 flop (N754S mutant) LBD. In contrast to the other examples shown, 
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13 does not coincide with the central twofold axis and therefore two independent molecules can be 
accommodated within the same binding pocket, as observed in the crystal structure depicted. (c) Crystal 
structure of 20 (LY404187) bound to the GluA2 flip LBD.  Again, only one molecule is shown for 
clarity as 20 also spans the central twofold axis. 
1.2.2 Ligand binding 
Crystal structures have been reported for several of the modulators shown in Tables 1, 2 and 3 bound 
to the LBD of GluA2. Specifically, protein-ligand structures have been reported for benzothiadiazines 
such as 13 (cyclothiazide),14 the benzamides 2 (aniracetam) 17 and 6 (CX614)17 and the sulfonamides 
2012 and 22.19 The different classes of modulator share distinct but overlapping binding sites, as detailed 
in Figure 2. In each case, the allosteric modulator sits at the interface between two LBD clamshells, and 
modulates the protein-protein interaction between the two subunits, preventing the conformational 
changes required to move the receptor to the desensitized state.   
 
 The binding mode of 2 is shown in Figure 2A. Compound 2 makes no hydrophilic interactions with 
protein atoms, and forms just one hydrogen bond with a network of solvent molecules occupying the 
buried hydrophobic pocket. Figure 2B shows the binding mode of 13 which forms a network of 
hydrogen bonds with the side-chains of Ser497 and Ser754, and with mainchain atoms of Pro494 and 
Ser497. The norbornyl moiety is buried within the hydrophobic pocket. Figure 2C shows the binding 
mode of 20 (LY404187). The isopropyl sulfonamide occupies the hydrophobic pocket, and forms a 
single hydrogen bond with Pro494. Considered together, these three structural classes map out the 
surface properties and explore much of the available volume within the allosteric site. The binding site 
is symmetrical, with two deep, mainly hydrophobic pockets separated by a hydrophobic saddle. 
Opportunities for hydrophilic interactions occur towards the extremities of the binding site, as 
demonstrated by the structure of 13 in Figure 2B. The hydrophobic pockets accommodate a network of 
solvent molecules, which can form interactions with lower potency modulators (e.g. 2) but can also be 
displaced by higher potency modulators such as 13 and 20. Compounds which occupy one or both of 
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these pockets appear to be advantageous, presumably as they both inhibit the conformational changes 
associated with desensitization, and simultaneously interact with the LBD monomers comprising the 
allosteric site to increase the stability of the activated state of the receptor.  
Biostructural data has greatly enhanced understanding of the mechanisms underlying both the normal 
function and the pharmacological modulation of AMPA receptors, and is certain to remain a key factor 
in the identification of novel modulators of AMPA receptor function. 
 
2. Chemical classes of AMPA receptor positive modulators. 
Over the years, a growing body of compounds spanning a variety of chemotypes has emerged from 
both the chemical and patent literature, with that number burgeoning considerably in recent times.  
Reporting of biological data has been complicated by the use of different cell and assay formats as well 
as differing measures of efficacy.  The main emphasis of this article is to provide an overarching view 
of the established and emerging chemotypes in the area of AMPA receptor modulators as well as giving 
some measure of the associated SAR. The review will focus on four predominant chemical classes as 
well as summarizing other significant compounds of interest. 
 
2.1 Benzamide derivatives 
The benzamides were one of the first series of AMPA receptor positive modulators. This series was 
discovered by researchers at the University of California following chemical modification of the 
putative nootropic compounds 1 (piracetam)24 and 225. In early work 1 had been shown to potentiate 
AMPA-induced 45Ca2+ uptake into neuronal cultures at a concentration of 10 μM.  Compound 2 has 
been shown to potentiate the L-glutamate evoked steady state currents at rat AMPA receptors with a 
low (ca >1 mM) potency with selectivity for flop over flip receptors. 
 
Early members of the benzamide series include 3 (CX546) 26,27,28  and 4.26, 27, 28, 29 These analogs, like 
compound 2, are weak potentiators of agonist evoked steady state currents with EC50 values greater than 
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100 μM. Much of the electrophysiology data on these compounds has been performed using fast 
applications of agonists and the measurements of deactivation time constants (as opposed to long 
agonist applications and measuring inhibition of desensitised currents). Whole system ex vivo slice 
electrophysiology has also been reported extensively for benzamide series compounds, measuring so-
called excitatory post-synaptic current or EPSC’s. The effects of the positive modulator on the binding 
of the agonist have been reported in several publications. Compounds 3 and 4 have been shown to slow 
the deactivation time constant 10-fold and 3.2-fold (rat native membranes), respectively and the slice 
electrophysiology data for compound 4 is reported as showing increases in EPSC half-width of 28% and 
amplitude of 68% at 2 μM. Compound 4 is reported as showing no effect on 5-fluorowillardine binding 
(FW, an AMPA receptor agonist) up to a concentration of 20 μM. Even more simplified analogues of 3 
have been claimed by researchers at Cortex. Compound 5 is claimed to increase the slice EPSC 
amplitude by 25% at a concentration of 300 μM.30 
Conformationally constraining 3 has given the more potent analogue 6.31, 32 Using slice 
electrophysiology, a 30 μM concentration of 3 is reported to increase the slice EPSC amplitude and 
half-width by approximately 40% and 80% respectively, to slow the deactivation time constant by a 
factor of 8.4 and to enhance FW binding to rat native receptors with an EC50 of 64 μM. 
Related conformationally constrained analogues include 7 33 and 8 34 that are claimed to increase the 
slice EPSC amplitude by 25% at concentrations of 30 μM and 300 μM, respectively. 
Structural modifications of 4 have led Cortex workers to the more potent analogue 935,29. This 
compound has been licenced to Organon (now Merck). Patch clamp electrophysiology indicates that 9 
is approximately 10-fold more potent than 4. Compound 9 is claimed to increase the slice EPSC 
amplitude by 10% (3 μM). 
The benz- and pyrido/thienyl-oxazepinone series of compounds have been disclosed by workers at 
Organon (now Merck). Compounds 1036 and 1137 are claimed to increase steady state currents in rat 
hippocampal neurones by 20 and 32%, respectively with no EC50 values reported. 
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Recent work from the Servier-Cortex collaboration has resulted in the disclosure of compounds such 
as 1238 which is claimed to have a two fold potentiation of the AMPA current (EC2X) of 0.1 µM in rat 
cortical cells by patch clamp electrophysiology. 
The only compounds from this class to have progressed to the clinic are 4, 43 (structure not disclosed) 
and 9.  Although 4 showed some early promise with modest effects on cognition being reported in 
studies with healthy human volunteers39 40, subsequent double-blind studies in schizophrenics failed to 
show any beneficial therapeutic effect, either as a monotherapy41 or as an add-on42 to standard 
antipsychotic drugs. Following up on the demonstration that 43 was able to improve cognitive 
performance in sleep-deprived monkeys, Cortex Pharmaceuticals reported that 43 had an alerting effect 
on sleep deprivation trials in healthy young men and produced some attenuation of cognitive deficits. 
However, that finding failed to be replicated in a double-blind placebo-controlled trial in volunteers 
undergoing simulated night shift work.43  Other more promising clinical data reported by Cortex include 
a phase IIa study in subjects with ADHD where 43 had a statistically significant effect on the 
hyperactivity subscale.  Further phase IIa studies with 43 have demonstrated that it is able to prevent the 
onset of respiratory depression induced by an opioid, while preserving the opioid’s pain-relieving 
effects.44 To date there has yet to be any clinical data reported for 9. 
Table 1.  Benzamide derivatives 
Compound Structure EC50 (μM) 
 
1 
NH2
O
N
O
 
 
ND 
 
2 O
O
N
O
 
 
>1000a 
 
3 
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O
O
N
 
 
1600 (est)b 
9
 
 4 
N
N
O
N
 
95b 
156c 
>1000c 
 
5 
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O
N
 
 
ND 
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O
O
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43.7b 
21d 
 
7 O
O
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O
O
O  
 
ND 
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O
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ND 
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NN
O
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14 
 
10 
O
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N
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ND 
 
11 
O
O
NS
 
 
ND 
 
12 O
N
N
N
O
N
O
F
 
 
ND 
a) measured at GluR 3/4o expressed in Xenopus oocytes; b) measured at rat hippocampal CA1 
pyramidal neurons; c) GluR4(i) in HEK-293 cells; d) GluR1(o) expressed in Human HEK cells; ND = 
data not disclosed 
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 2.2 Cyclothiazide & related compounds 
Another significant class of AMPA positive allosteric modulator that has emerged are the 
benzothiadiazine derivatives. Such compounds are generally derived from 13 (cyclothiazide, CTZ), 
which was originally designed as a diuretic but has since been profiled extensively as a positive 
modulator of the AMPA receptor, (data in Table 2).45  Biostructural data detailing the binding mode of 
13 to the AMPA ligand binding domain is discussed above.  Perhaps the most advanced member of this 
class is the Servier compound 14 (S-18986), which exhibited an EC2x of 60 μM46 in the current induced 
by AMPA when added to Xenopus oocytes.  The Servier group demonstrated that only the (S)-
enantiomer was effective as an AMPA positive allosteric modulator. In spite of its relatively lower 
potency compared to 13, compound 14  is able to penetrate the blood-brain barrier, thus enabling in 
vivo investigation.47 In vivo pharmacological studies using the object recognition test in rat showed that 
14 when dosed from 0.3 to 3 mg/kg p.o. improved the retention of memory and at the 0.3 mg/kg dose 
counteracted the effect of age-related memory deficits.48 
Subsequent studies have shown that analogues derived from 14 have been shown to have superior 
levels of potency (e.g. 15 EC2x = 8.8 μM).45  It remains to be seen if this enhanced potency leads to 
improved in vivo efficacy in, for example, cognition models. 
 
 
Table 2.  Cyclothiazide & related species. 
Compound Structure EC2X (μM) 
 
13 N
H
NH
S
O O
Cl
O2S
NH2
 
 
1.6a 
11
 
 14 
NH
S
O O
Cl
N
 
 
60a 
 
15 
N
NH
S
O O
N
 
 
8.8a 
a) measured in Xenopus oocytes. 
 
2.3 Sulfonamide derivatives 
The first examples in this class of AMPA positive modulators were reported by Lilly in 2000.49 The 
progenitor alkyl-sulfonamide 16 derived from high throughput screening using a recombinant assay in 
which compounds were assessed for their ability to potentiate the response mediated by 100 μM L-
glutamate in a stable cell line expressing homomeric GluR4 flip receptors.28 In this assay compound 16 
displayed potency (EC50 = 19.6 μM) only five fold lower than 13, and significantly higher than that for 
previously reported benzamide modulators such as 4. Initial efforts by the Lilly group to further 
improve the potency of the modulator 16 established relatively tight SAR around the alkyl-sulfonamide 
region. For example, ethyl- and iso-propyl analogues showed around four-fold improved modulation 
compared to the parent methyl sulfonamide 16, whereas derivatives with slightly larger n-butyl and 
benzyl groups displayed complete loss of activity in the AMPA assay (EC50 >100 μM).28 Similarly, a 
progressive increase in size of the benzylic group showed the methyl to be the most optimal in this 
position. The region around the distal aromatic ring also proved important for AMPA potency, but more 
tolerant to structural changes. For instance, whereas deletion analogue 17 showed a significant loss of 
activity (EC50 = 1980 μM),19 replacement of the o-fluorophenyl group in 16 with structurally diverse 
groups such as a tert-butyl 18 and 3-thiophenyl 19 resulted in a 5-10 fold jump in the potency (EC50 = 
1.2 μM and EC50 = 4.5 μM, respectively). Studying the effect of substitution around the distal aryl ring 
in combination with the most optimal iso-propyl sulfonamide functionality, Lilly scientists observed a 
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two order of magnitude enhancement in potency for analogues containing methyl, formyl, amino or 
nitrile groups in the 4’position.  
As one of the most potent AMPA modulators reported in the literature (GluR4 EC50 = 0.29 μM), the 
nitrile analogue (±) 20 (as extensively profiled both in vitro and in vivo, and became an important and 
widely applied tool for further elucidation of the role of AMPA receptors in neurological disorders.50 
Equipotent at GluR2 (EC50 = 0.15 μM), 20 was shown to be moderately selective over the other two 
isoforms, GluR1 (EC50 = 5.65 μM) and GluR3 (EC50 = 1.66 μM),51 and essentially inactive at a range 
of ion channels, including other ionotropic glutamate receptors such as kainate or NMDA, and voltage 
gated potassium, sodium or calcium channels. 52  In addition, 20 was shown to have around 10 fold 
selectivity for flip (i) versus flop (o) receptors (GluR2o EC50 = 1.44 µM). In terms of its mechanism of 
action, whole-cell voltage clamp using rat prefrontal cortex neurons studies revealed that 20 potentiates 
AMPA receptors by blocking the channel desensitization and therefore favoring an agonist-bound open 
state.50 
The observed high potency in the recombinant GluR4 assay translated into robust potentiation of 
AMPA receptors in in vitro preparations, as well as efficacy in relevant in vivo models. For example, 
electrophysiology studies in Purkinje neurons have shown 20 to be around 1000-fold more potent than 
benzamide modulators such as 4.53 In vivo electrophysiological studies of 20 indicated a dose dependent 
increase in firing rate on rat hippocampal neurones with an ED50 of 12 μg/kg.54 Pre-clinical studies with 
20 demonstrated improvements in models of working memory such as water maze and passive 
avoidance,50 providing further evidence for the link between glutamatergic hypofunction and cognitive 
deficits in schizophrenia. It has also been reported that sub-chronic treatment of rats with 20 produced 
an increase in expression of BDNF, a neural growth factor for which reduced levels have been 
associated with depression, suggesting that this compound could also have utility as an anti-depressant. 
8  
Building on the promising preclinical data, Lilly scientists continued optimization efforts around 20, 
which resulted in the discovery of a bis-sulfonamide series, from which compound 21 has progressed 
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into clinical studies.55, 56 Very little preclinical data have been reported for this compound. It has been 
disclosed that compound 21 showed efficacy in preclinical cognitive models, such as the water maze 
and acquisition and retention in the radial arm maze, thus having a similar profile to compound 20.8 In 
the clinic, 21 was found safe and well tolerated in human volunteers at doses of up to 5 mg.57 However, 
in a phase II clinical study on 181 patients with Alzheimer’s disease, 21 failed to show any effect on 
cognition.58 The authors of the study suggested that this could potentially be due to a sub-optimal 
dosing regime (0.2 mg BID for 28 days followed by 1.0 mg BID thereafter up to a maximum of 8 
weeks). 
A recently published X-ray structure of compound 22, a closely related symmetrical analogue of 21, 
co-crystallised with a soluble GluR2 construct revealed an interesting binding mode with the bis-
sulfonamide imbedded into the GluR2 homodimeric interface.19 The two sulfonamide moieties of 22 
were shown to form an identical hydrogen-bonding pattern within the same allosteric site on the two 
dimerised GluR2 subunits, whereas the biaryl linker makes hydrophobic contacts with a saddle-like 
formation in the central part of the binding site created by Pro494 and Pro494’ residues. The fact that 
bis-sulfonamides with greatly simplified structure such as 23a-c59 still maintained high potency60 
(Table 3) suggests that the isopropyl sulfonamide moiety is responsible for most of the ligand binding in 
this series. Flexibility in the SAR of the linker region has been further demonstrated by insertion of an 
amide spacer resulting in compound 24, with potency similar to the most active potentiators in the 
biaryl sulfonamide series (GluR4 EC50 = 0.52 µM).61 
Further optimization efforts around this chemotype led scientists at Lilly to produce a range of 
constrained analogues, which generally showed at least an order of magnitude greater potency than the 
related open-chain ligands.62  For instance, a 4-bromo derivative in the 2-aryl propylsulfonamide series 
(±) 25 showed significantly lower potency in the GluR4 assay (26% at 3 μM) than the corresponding 
cyclopentane derivative (±) 26 (EC50 = 0.52 µM). With EC50 value of 23 nM, iodo derivative (R,R) 27 
was the most potent AMPA modulator among 29 examples reported in this series. 
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A series of related constrained analogues have also been disclosed by GlaxoSmithKline. Their work 
around this chemotype focused on insertion of heteroatoms into the molecule, possibly to optimize 
physicochemical properties, resulting in AMPA potentiators such as 28 (EC50 = 1.6 µM), 29 and 30. 
63,64,65 In their earlier efforts the GlaxoSmithKline group took an alternative constraining approach, 
which led to discovery of indane series, typified by 31 (EC50 = 3 µM) and 32 (EC50 = 10 µM).66,67 
Limited SAR data disclosed by GlaxoSmithKline suggest generally lower AMPA potency of their 
constrained analogues when compared to those claimed by the Lilly group. A recent report describes 
how 31 had promising PK & further profiling enable the compound to reach phase I clinical trials for 
cognitive impairment associated with schizophrenia. 68 
Most recently Pfizer have also disclosed their interest in AMPA modulators, with a patent application 
around a constrained sulfonamide series, exemplified by 33.69 To date, no information on the stage in 
development of this series has been reported. 
Table 3. Sulfonamide derived systems. 
Compound Structure EC50 (μM) 
16 
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F  
19.6a 
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H
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1980b 
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1.2a 
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0.15a 
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0.87c 
23 NH ()n
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n=0,1,2  
a(n=0) 2.88d 
b(n=1) 0.91d 
c(n=2) 0.66d 
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0.52a 
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26%@3μMa 
26 NH SO2Br
 
0.52a 
27 NH SO2I
 
0.023a 
28 
N
NH SO2
N
O2S
 
1.6e 
16
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ND 
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2.5e 
 
32 
S
N
H
SO2
 
10e 
33 
N
NH
SO2
 
<10f 
a) Recombinant human GluR4(i) expressed in HEK-293; b) Recombinant rat GluR2 flip expressed in 
Xenopus oocytes; c) Recombinant rat GluR4 flip expressed in X. Laevis oocytes; d) Recombinant human 
GluR1(i) expressed in HEK-293; e) Recombinant human GluR2; f) AMPA ES Cell FLIPR assay; ND 
data not disclosed 
 
2.4 Indazole based derivatives 
Workers at GlaxoSmithKline have shown an interest in the tetrahydroindazole type compounds as 
evidenced in some recent patent applications.70  Compounds typified by 34 have been claimed as 
positive allosteric modulators of the AMPA receptor, with subsequent patent applications demonstrating 
that modification of both the fused ring system and the amide portion are also feasible.71 
Characterisation by whole cell patch-clamp electrophysiology indicated that compounds from this class 
applied at a concentration of 10 nM showed a potentiation of between 14 and 79% of the current evoked 
by 30 μM AMPA. 
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Compounds such as 35 have been disclosed by GSK as clinical candidates for the treatment of 
cognitive defects in schizophrenia71. In vitro characterization by electrophysiology indicates that 
compounds show similar levels of efficacy to the progenitor series.  Subsequent work has shown that 
replacement of the fused ring system substituent with 5-pyridyl or 5-cyclopropyl moieties is tolerated.72 
Most recently, a hybridization approach was applied to furnish compounds of the type 36 and 37 
through combining SAR from the pyrazole series with the previously disclosed indane based 
derivatives.73 
A 2008 patent application from Organon (now Merck) revealed a further series of pyrazole 
derivatives exemplified by compound 38.74 Variation of both the pyrazole ring and peripheral amide 
moiety is also presented in the same patent application. 
Table 4. Indazole derived modulators 
Compound Structure EC50 (μM) 
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a) measured at GluR2; b) measured at GluR1 
2.5 Other chemotypes of interest 
Lastly, a number of more structurally diverse compounds have appeared in the literature over the last 
few years each representing a unique chemotype. 
Further efforts from Lilly75 have disclosed the biarylpyrrole acid compounds exemplified by 39.  This 
compound evolved through a hits to leads program and is believed to be the most potent compound in 
the series.  The compound exhibited similar potencies against both flip and flop forms of two different 
subunits (GluR4i = 56 nM, GluR4o = 53 nM, GluR2i = 82 nM, GluR2o = 73 nM) and has been selected 
for further biological studies.  The results of these studies will undoubtedly provide insight into the 
utility or otherwise of high potency AMPA receptor modulators as cognition enhancers. 
Workers from CoCensys (now Purdue) have disclosed a series of benzopyran derived analogues76  
typified by 40, (EC2x = 1.6 μM) and Boehringer Ingleheim have published a patent application on a 
class of benzothiazine analogues77 (41, no data reported).  
More recently, GSK have consolidated their efforts in the area of AMPA receptor modulators through 
the publication of a patent application concerning a series of (arylimino)dihydrothiazoles typified by 
compound 42.78 When characterised by whole cell patch-clamp electrophysiology, compounds from 
this class applied at a concentration of 10 nM showed a potentiation of between 15 and 42% of the 
current evoked by 30 μM AMPA. 
Table 5. Miscellaneous AMPA modulators 
Compound Structure EC50 (μM) 
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a) measured in GluR4; b) measured in X. Laevis oocytes; c) measured in GluR2; ND data not 
disclosed 
 
2.6 Summary and Outlook 
The last few years has witnessed a significant expansion in activity in the area of positive allosteric 
modulators of the AMPA receptor and this review has aimed to provide an overview of the major 
chemotypes developed thus far.  Significant advances have been made in our understanding of the 
molecular basis of how many of these emerging templates exert their biological effect at the receptor 
and this will undoubtedly facilitate the discovery of new templates as well as enabling the optimization 
of existing lead series.  We anticipate that in the next few years the results from on-going clinical efforts 
in the area will come to fruition and is likely to ignite further interest in AMPA receptor modulators for 
the treatment of a number of debilitating neurological disorders. 
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